FDA Approves First Factor XIa Inhibitor Sunharbo for Stroke Prevention
The US Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets as the first factor XIa inhibitor. It is indicated for use alongside antiplatelet therapy to lower the risk of stroke in adults who have experienced a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.
Approval was supported by clinical trial findings showing a reduced risk of ischemic stroke compared to placebo. However, safety data showed increased major bleeding risks in patients over 75 years old and during the initial treatment period, alongside higher rates of gastrointestinal bleeding and diarrhea.
The regulatory agency advises against using Sunharbo with combined P-gp and strong CYP3A4 inducers or in patients with moderate to severe hepatic impairment. It should also be withheld before elective surgeries, invasive procedures, or following acute stroke thrombolysis, and it is not approved for patients with atrial fibrillation.
Key points
- Sunharbo 50 mg tablets are the first approved factor XIa inhibitor for secondary stroke prevention.
- Indicated in combination with antiplatelet therapy for recent non-cardioembolic ischemic stroke or high-risk TIA.
- Major bleeding rates increased in patients older than 75 and during the first 90 days of treatment.
- Concomitant use with combined P-gp and strong CYP3A4 inducers is not recommended.
What it means for you
Clinicians managing secondary stroke prevention should note the approval of this new factor XIa inhibitor class option and carefully review patient risk factors, including age and bleeding history. Healthcare professionals in Pakistan should check with DRAP for local registration status and guidance before considering availability. Always follow prescribing information and do not alter specific patient regimens without appropriate clinical evaluation.
FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.